OREGON THERAPEUTICS
Oregon Therapeutics is developing XCE853 : disruptive targeted therapy “first in class” and “best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action: inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into the clinical phase for the treatment of cancer within 2 years. Based on the scientific rationale to exploit the metabolic vulnerability of some cancers, the two priority indications are ovarian cancer and advanced pancreatic cancer.
OREGON THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.oregon-therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+33 0 6 01 03 43 43
Email Addresses:
[email protected]
Total Funding:
0
Similar Organizations
ELARA Pharmaceuticals
ELARA Pharmaceuticals offers research and pharmaceutical development services for new anti-cancer drugs.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Zhongnong Ying Tailin Prefecture
Zhongnong Ying Tailin Prefecture is a developer of antibacterial peptide.
Investors List
AGORANOV
AGORANOV investment in Venture Round - Oregon Therapeutics
Official Site Inspections
http://www.oregon-therapeutics.com
- Host name: cluster030.hosting.ovh.net
- IP address: 145.239.37.162
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
